临床中西降压药物的成本效果分析综合评价

目的观察4种降压药的降压效果、症状改善、不良反应及对高血压病患者生活质量(QOL)的影响,并对4种药物作成本-效果分析(CEA).方法将292例轻、中度高血压病患者,随机分成4组,疗程均为6周.QOL测定采用SF-36量表,CEA综合评价采用效果决策模式.结果按综合评价得分高低依次为:吲达帕胺(3.65)、珍菊降压片(3.30)、苯磺酸氨氯地平(2.90)、盐酸苯那普利(2.35).结论4种降压药不仅有良好的降压效果,改善症状积分、且不良反应也较少;评价和选择降压药物,应结合QOL测评;CEA综合评价表明珍菊降压片列第2位,提示应重视中西结合复合降压制剂的应用.

CEA comprehensive evaluation for western and traditional Chinese hypotensive drugs

OBJECTIVE To make a cost-effectiveness analysis (CEA) comprehensive evaluation for 4 hypotensive drugs by observing the effects of drugs on blood pressure lowering, symptom improving, and adverse effect and quality of life (QOL) influencing. METHOD Two hundred and ninety-two patients with mild to moderate hypertension were divided into 4 groups at random and treated with compound Zhenjujiangya pill, benazepril, amlodipine and indapamide respectively with a therapeutic course of 6 weeks. QOL was measured with FS-36 questionnaire and efficacy policy model was applied for comprehensive evaluation of CEA.RESULTS Through CEA a comprehensive evaluation was made in order as follows: indapamide 3.65 which was the best, and then Zhenjujiangya pill 3.30, amlodipine 2.90 and benazepril 2.35. CONCLUSION The 4 drugs can not only lower blood pressure but also improve clinical symptoms with less adverse effect. It is of great practical significance to evaluate hypotensive drugs by combining QOL appraisal. The position of Zhenjujiangya pill in CEA order suggests that more attention should be paid to the hypotensive drugs integrated traditional and western medicine.